← FDA DRUG APPROVALS

FDA NDA · NDA212640

EXSERVAN

Sponsor: AQUESTIVE

APPLICATION
NDA212640
TYPE
NDA
ORIGINAL APPROVAL
2019-11-22
LATEST ACTION
2020-05-11
ROUTE
ORAL
DOSAGE FORM
FILM
MARKETING STATUS
Discontinued

Products

EXSERVAN · ReferenceDiscontinued
RILUZOLE 50MG · FILM · ORAL

Approval history

2020-05-11Labeling · Supplement 1 · standard — Label ↗AP
2019-11-22Type 3 - New Dosage Form · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →